259 related articles for article (PubMed ID: 2825685)
21. Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig.
Desquand S; Touvay C; Randon J; Lagente V; Vilain B; Maridonneau-Parini I; Etienne A; Lefort J; Braquet P; Vargaftig BB
Eur J Pharmacol; 1986 Aug; 127(1-2):83-95. PubMed ID: 3019727
[TBL] [Abstract][Full Text] [Related]
22. Binding of [3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes.
Herbert JM; Laplace MC; Maffrand JP
Biochem Pharmacol; 1993 Jan; 45(1):51-8. PubMed ID: 8381007
[TBL] [Abstract][Full Text] [Related]
23. The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity.
Mandi Y; Farkas G; Koltai M; Beladi I; Mencia-Huerta JM; Braquet P
Immunology; 1989 Jul; 67(3):370-4. PubMed ID: 2759659
[TBL] [Abstract][Full Text] [Related]
24. Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists.
Vogensen SB; Strømgaard K; Shindou H; Jaracz S; Suehiro M; Ishii S; Shimizu T; Nakanishi K
J Med Chem; 2003 Feb; 46(4):601-8. PubMed ID: 12570381
[TBL] [Abstract][Full Text] [Related]
25. Inhibition by calcium channel blockers of the binding of platelet-activating factor to human neutrophil granulocytes.
Filep JG; Földes-Filep E
Eur J Pharmacol; 1990 Nov; 190(1-2):67-73. PubMed ID: 1963851
[TBL] [Abstract][Full Text] [Related]
26. Proof of the involvement of platelet activating factor (paf-acether) in pulmonary complex immune systems using a specific paf-acether receptor antagonist: BN 52021.
Touvay C; Vilain B; Taylor JE; Etienne A; Braquet P
Prog Lipid Res; 1986; 25(1-4):277-88. PubMed ID: 2827186
[No Abstract] [Full Text] [Related]
27. Effects of C-reactive protein on human neutrophil granulocytes challenged with N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor.
Filep J; Földes-Filep E
Life Sci; 1989; 44(8):517-24. PubMed ID: 2538700
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists.
Nguyên P; Petitfrère E; Potron G
Thromb Res; 1995 Apr; 78(1):33-42. PubMed ID: 7778064
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins.
Paubert-Braquet M; Hosford D; Klotz P; Guilbaud J; Braquet P
J Lipid Mediat; 1990; 2 Suppl():S1-4. PubMed ID: 1966810
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic characterization of the rabbit neutrophil receptor for platelet-activating factor.
Paulson SK; Wolf JL; Novotney-Barry A; Cox CP
Proc Soc Exp Biol Med; 1990 Nov; 195(2):247-54. PubMed ID: 2172997
[TBL] [Abstract][Full Text] [Related]
31. Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; evaluation in a pig kidney-human blood xenoperfusion model.
Cruzado JM; Torras J; Riera M; Lloberas N; Herrero I; Condom E; Martorell J; Alsina J; Grinyó JM
Clin Exp Immunol; 1998 Jul; 113(1):136-44. PubMed ID: 9697996
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate.
Bruijnzeel PL; Warringa RA; Kok PT; Kreukniet J
Br J Pharmacol; 1990 Apr; 99(4):798-802. PubMed ID: 2163279
[TBL] [Abstract][Full Text] [Related]
33. Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.
Filep JG; Sirois MG; Rousseau A; Fournier A; Sirois P
Br J Pharmacol; 1991 Dec; 104(4):797-804. PubMed ID: 1667286
[TBL] [Abstract][Full Text] [Related]
34. Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus.
Lee CM; Jiang LM; Shang HS; Hon PM; He Y; Wong HN
Br J Pharmacol; 1991 Jul; 103(3):1719-24. PubMed ID: 1657264
[TBL] [Abstract][Full Text] [Related]
35. Role of platelet-activating factor in long-term potentiation of the rat medial vestibular nuclei.
Grassi S; Francescangeli E; Goracci G; Pettorossi VE
J Neurophysiol; 1998 Jun; 79(6):3266-71. PubMed ID: 9636125
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of platelet-activating factor- and zymosan-activated serum-induced chemotaxis of human neutrophils by nedocromil sodium, BN 52021 and sodium cromoglycate.
Bruijnzeel PL; Warringa RA; Kok PT
Br J Pharmacol; 1989 Aug; 97(4):1251-7. PubMed ID: 2551444
[TBL] [Abstract][Full Text] [Related]
37. Effect of the platelet-activating factor antagonist BN 52021 on human natural killer cell cytotoxicity.
Mandi Y; Farkas G; Koltai M; Beladi I; Braquet P
Int Arch Allergy Appl Immunol; 1989; 88(1-2):222-4. PubMed ID: 2540096
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of PAF antagonists using human neutrophils in a microtiter plate assay.
Dewald B; Baggiolini M
Biochem Pharmacol; 1987 Aug; 36(15):2505-10. PubMed ID: 3649232
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte-macrophage colony-stimulating factor increases the synthesis of leukotriene B4 by human neutrophils in response to platelet-activating factor. Enhancement of both arachidonic acid availability and 5-lipoxygenase activation.
McColl SR; Krump E; Naccache PH; Poubelle PE; Braquet P; Braquet M; Borgeat P
J Immunol; 1991 Feb; 146(4):1204-11. PubMed ID: 1846895
[TBL] [Abstract][Full Text] [Related]
40. Presence of specific platelet-activating factor binding sites in the rat retina.
Thierry A; Doly M; Braquet P; Cluzel J; Meyniel G
Eur J Pharmacol; 1989 Apr; 163(1):97-101. PubMed ID: 2545464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
